Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), filed a Form 4 on August 14, 2026, reporting the vesting of Performance Share Units and a related tax withholding transaction dated August 12, 2026.

Key Highlights

  • PSU vesting: 29,849 shares of common stock were acquired by Khattar via transaction code M (conversion of derivative security) at $0 per share on August 12, 2026.
  • Tax withholding: 12,642 shares were disposed of at $46.57 per share by the company to satisfy tax withholding requirements in connection with the PSU vesting.
  • Direct holdings after transactions: Khattar directly beneficially owned 1,258,351 shares of common stock following the reported transactions.
  • Indirect holdings: An additional 958,100 shares are held indirectly by Khattar through the KBT Trust.
  • PSU award origin: The Performance Share Units were awarded on February 19, 2025, with individual performance objectives established on May 3, 2025.
  • Signatory: The form was signed by Timothy C. Dec as attorney-in-fact on August 14, 2026.

Khattar PSU Vesting and Share Withholding at Supernus Pharmaceuticals

According to the filing, Jack A. Khattar, who serves as both a Director and as President and CEO of Supernus Pharmaceuticals, Inc., reported two transactions in the company's common stock occurring on August 12, 2026. The first was an acquisition of 29,849 shares through the conversion of Performance Share Units at a price of $0, reflecting the vesting of those units rather than an open-market purchase.

The filing discloses that the Performance Share Units involved were originally awarded to Khattar on February 19, 2025. According to the filing's explanation of responses, "a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025." Following the vesting, 12,642 shares were withheld by the company at $46.57 per share to cover tax withholding obligations, a transaction coded F in the filing.

After both transactions, the filing reports that Khattar directly held 1,258,351 shares of Supernus common stock. In addition, the filing identifies 958,100 shares held indirectly through the KBT Trust. The Performance Share Unit derivative position was reduced to zero following the vesting event, as reported in Table II. The form was filed by one reporting person and was not indicated as an amendment to a prior filing.

What Was Disclosed

The Form 4 filed August 14, 2026, discloses the August 12, 2026 vesting of 29,849 Performance Share Units held by Supernus Pharmaceuticals CEO Jack A. Khattar, and the withholding of 12,642 shares at $46.57 each to satisfy related tax obligations.